Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phase II study to evaluate the efficacy and safety of mirogabalin for CIPN in patients with gastrointestinal cancer.

ABSTRACT: Interventions: Initial dose of mirogabalin orally twice daily, then titrated at intervals of at least 1 week to a maintenance dose orally twice daily. Primary outcome(s): Change in 24-hour pain (including numbness) average NRS (Numeric Rating Scale) from the start of mirogabalin administration to 6 weeks. Study Design: Single arm Non-randomized

DISEASE(S): Esophageal Cancer, Gastric Cancer, Small Bowel Cancer, Colon Cancer, Pancreatic Cancer

PROVIDER: 103511 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Efficacy of olanzapine for relief of nausea with incomplete bowel obstruction in advanced cancer patient: pragmatic randomized controlled trial

Project description:Interventions: Group A: olanzapine (5 mg) Zydis or tablet 5mg/day (evening) orally Group B: 1) metoclopramide (5 mg) tablet 30 mg/day (morning/noon/evening) orally or 2) metoclopramide (10 mg) injectable solution 20 mg/day (intermittent or continuous) subcutaneous or drip infusion Primary outcome(s): Changes in the average value of nausea for 24 hours with Numeric Rating Scale (NRS) Study Design: Parallel Randomized

| 2625706 | ecrin-mdr-crc

Phase Ib of olaparib and capivasertib

Project description:Background: Combining poly(ADP-ribose) polymerase (PARP) with phosphatidylinositol-3-kinase (PI3K) pathway inhibitors is supported by strong preclinical rationale. We sought to assess safety and a recommended phase 2 dose (RP2D) for the PARPi olaparib combined with the AKT inhibitor, capivasertib, and evaluate molecular markers of response and resistance. Methods: As part of a larger phase 1b trial, we performed a safety lead in of olaparib and capivasertib followed by expansion (n=24) in endometrial, triple negative breast, ovarian, fallopian tube, or peritoneal cancer. Olaparib 300mg orally twice daily and capivasertib orally twice daily on a 4 day on/3 day off schedule were evaluated. Two dose levels (DL) were planned: capivasertib 400mg (DL1); capivasertib 320mg (DL-1). Patients underwent biopsies at baseline and after 28 days.

| EGAS00001004930 | EGA

RNA-seq of classical and intermediate monocytes from people with osteoarthritis pain

Project description:In this study, blood was collected from human participants with osteoarthritis pain, along with radiographic scores (Kellgren & Lawrence Score (KL)) and pain scores (Numerical Rating Scale (NRS)). Peripheral blood mononuclear cells were isolated from whole blood, and classical and intermediate monocytes were further isolated using fluorescence-activated cell sorting. mRNA was then extracted from monocytes for sequencing.

2024-12-31 | E-MTAB-14402 | biostudies-arrayexpress

Gene expression profiling using RNA-Seq data of MMTV-Wnt1 tumor tissue from mice treated with E7386

Project description:We conducted an RNA-Seq analysis using total RNA extracted from MMTV-Wnt1 tumor tissues resected from mice orally administered E7386 at 25 or 50 mg/kg twice daily, or vehicle, for 3 days (Day 4) or 7 days (Day 8) and examined the differentially expressed gene levels compared with vehicle at days 4 and 8.

2020-12-21 | GSE158713 | GEO

Expression data from female SD rats with access to lifelong exercise

Project description:Gene expression and phenotypic consequences of laboratory housing in rats. Disease related-phenotypes and associated gene expressions of sedentary animals (living solely in a standard cage) were compared with animals that had access to twice-weekly one-hour physical activity in a large box (PA) and with those that had access to voluntary running wheel exercise (EX). Keywords: exercise dose reponse, sedentary, twice weekly physical activity, daily exercise

2006-07-01 | GSE5085 | GEO

Study on the usefulness and safety of warmied infusions and local hot fomentations for vascular pain-like symptoms caused by peripheral intravenous administration of oxaliplatin

Project description:Interventions: 1st time chemotherapy 1.During heating is described in the report 2.If vascular pain happened, then the warming infusion is start. 3.NRS is performed for 5min, 10min, 15min. Subsequent check is performed every 15 minutes.. 4.Patient’s report is performed from day 1 to day 8. Subsequently 1.Patients select one of the following before the start of infusion. i)Warming infusion is performed from the time of the appearance of vascular pain. ii)Performed prophylactically from the beginning. Not select all. Primary outcome(s): NRS:Numeric Rating Scale Study Design: Single arm Non-randomized

| 2625776 | ecrin-mdr-crc

RNAseq data on HDAC Class IIa inhibitor (CHDI-00390576) dosed R6/2 mice.

Project description:R6/2 and WT mice treated orally twice a day with vehicle (10% HPβCD), and R6/2 mice treated with either 30 or 100 mg/kg orally twice a day CHDI-00390576. CHDI-00390576 is a Class IIa HDAC inhibitor. Mice were dosed from 4 - 12 weeks of age.

2017-09-23 | GSE104086 | GEO

RNAseq data on HDAC Class IIa inhibitor (CHDI-00390576) dosed Q175 mice.

Project description:WT and Q175 heterozygous (het) mice treated orally twice a day with vehicle (10% HPβCD), and Q175 mice treated with either 30 or 100 mg/kg orally twice a day CHDI-00390576. CHDI-00390576 is a Class IIa HDAC inhibitor. Mice were dosed from 4 weeks to 6 months of age.

2017-09-23 | GSE104064 | GEO

55f16af1-8921-4df8-aed3-1ae1f59da15b - samples

Project description:Androgen deprivation therapy treated patients (n=11) were recruited from an open label neoadjuvant phase II study in which patients with high-risk disease received a ‘supercastration’ regimen consisting of degarelix 240/80 mg subcutaneously every four weeks; abiraterone acetate 500 mg orally daily titrating upwards every two weeks by 250 mg to a final dose of 1000 mg daily; bicalutamide 50 mg orally daily; and prednisolone 5 mg orally twice daily for a total of 6 months (Australian New Zealand Clinical Trials Registry 12612000772842). Untreated patients with similar pre-treatment characteristics were obtained from a prospective prostatectomy biorepository22,23. Prior to ligation of the dorsal venous complex and prostate pedicles, the anterior prostate was defatted and the specimen was removed immediately, placed in a sterile container and transferred on ice for long-term storage in the vapour phase of liquid nitrogen. A total of 50–100 µg of adipose tissue was separated from fresh frozen samples stored at −160°C. RNA was isolated using the Qiagen RNeasy Lipid Tissue Mini Kit and eluted in 35 µL nuclease-free water. 0.5–1 µg of total RNA was used as the input for cDNA library synthesis using TruSeq RNA Sample Prep Kit v2 (Illumina), and libraries were constructed according to manufacturer’s instructions. Samples were sequenced on a HiSeq 2500 (Illumina) using 101 base paired-end chemistry, aiming for 50 million mapped paired-end reads per sample.

| EGAD00001004971 | EGA

A Study Comparing Capecitabine Capsule 500 mg (IntasPharmaceuticals Ltd., India) To The Reference Listed Drug XelodaÂ(Capecitabine 500 mg; Roche Pharmaceuticals) In Patients Of BreastCancer Or Colorectal Cancer Under Fed Condition

Project description:Intervention1: Capecitabine Extended Release Capsule 500 mg (Intas Pharma) : Dose: 1250 mg/m2, Frequency: twice daily, Mode of Administration: orally, Duration of treatment: One week Control Intervention1: XelodaÂ (Capecitabine) film coated tablets 500 mg (Roche Pharmaceuticals) : Dose: 1250 mg/m2, Frequency: twice daily, Mode of Administration: orally, Duration of treatment: One week Primary outcome(s): AUCTimepoint: Day 07 and Day 14

| 2577537 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data